Rafael Bayarri Olmos, PhD
Cards
About
Titles
Associate Research Scientist
Education & Training
- PhD
- Copenhagen University, Faculty of Health and Medical Sciences, PhD degree in Molecular Immunology (2018)
- MSc
- Copenhagen University, Faculty of Science, Master's degree in Biotechnology (2013)
- BSc
- University of Leon, Faculty of Biology and Biotechnology, 5-year degree in Biotechnology (2011)
Research
Publications
2023
Functional Analysis of a Novel Complement C5a Receptor 1-Blocking Monoclonal Antibody
Cyranka L, Mariegaard I, Skjødt M, Bayarri-Olmos R, Mollnes T, Garred P, Rosbjerg A. Functional Analysis of a Novel Complement C5a Receptor 1-Blocking Monoclonal Antibody. Journal Of Innate Immunity 2023, 15: 836-849. PMID: 37952515, PMCID: PMC10691831, DOI: 10.1159/000535084.Peer-Reviewed Original ResearchConceptsC5a receptor 1C5aR1 inhibitionPolymorphonuclear leukocytesComplement C5a receptor 1Receptor 1Monoclonal antibodiesWhole bloodActivation markers CD11bIsolated polymorphonuclear leukocytesPotential therapeutic candidateInflammatory disease treatmentWhole blood modelCalcium flux assaysCell-binding studiesMouse monoclonal antibodyC5a-C5aR1Marker CD11bTherapeutic candidateHuman whole bloodC5aCalcium fluxComplement systemC5aR1Hybridoma clonesDisease treatmentDiverging humoral and cellular immune responses due to Omicron—a national study from the Faroe Islands
Petersen M, Pérez-Alós L, Kongsstovu S, Eliasen E, Hansen C, Larsen S, Hansen J, Bayarri-Olmos R, Fjallsbak J, Weihe P, Garred P. Diverging humoral and cellular immune responses due to Omicron—a national study from the Faroe Islands. Microbiology Spectrum 2023, 11: e00865-23. PMID: 37909772, PMCID: PMC10714973, DOI: 10.1128/spectrum.00865-23.Peer-Reviewed Original ResearchConceptsT cell responsesOmicron infectionHumoral responseUnvaccinated individualsImmune responseRobust T cell responsesSARS-CoV-2 Omicron variantPositive T-cell responsesDetectable humoral responseLow humoral responseLower humoral immune responseT cell immunityCellular immune responsesHumoral immune responsePrior vaccinationThird doseHumoral immunityImmune evasionOmicron variantInfectionInfection statusImmunityVaccinationNational studyResponseMAP‐2:CD55 chimeric construct effectively modulates complement activation
González‐del‐Barrio L, Pérez‐Alós L, Cyranka L, Rosbjerg A, Nagy S, Prohászka Z, Garred P, Bayarri‐Olmos R. MAP‐2:CD55 chimeric construct effectively modulates complement activation. The FASEB Journal 2023, 37: e23256. PMID: 37823685, DOI: 10.1096/fj.202300571r.Peer-Reviewed Original ResearchDistinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies
Jarlhelt I, Pérez-Alós L, Bayarri-Olmos R, Hansen C, Petersen M, Weihe P, Armenteros J, Madsen J, Nielsen J, Hilsted L, Iversen K, Bundgaard H, Nielsen S, Garred P. Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies. Microbiology Spectrum 2023, 11: e01796-23. PMID: 37738355, PMCID: PMC10580960, DOI: 10.1128/spectrum.01796-23.Peer-Reviewed Original ResearchSARS-CoV-2 infectionLong-term humoral immunitySARS-CoV-2 IgCOVID-19 vaccineInfection-induced immunityAntibody responseReceptor-binding domainSARS-CoV-2Viral spike proteinHumoral immunityImmune responseSARS-CoV-2 antibody responseInfected individualsInfection-induced immune responsesReceptor-binding domain antibodiesSpecific IgLong-term immune responseDurability of immunitySpike proteinProtective antibody responsesSandwich ELISACOVID-19 infectionGeneralized mixed modelNew significant increaseS proteinPrevious immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Pérez-Alós L, Hansen C, Almagro Armenteros J, Madsen J, Heftdal L, Hasselbalch R, Pries-Heje M, Bayarri-Olmos R, Jarlhelt I, Hamm S, Møller D, Sørensen E, Ostrowski S, Frikke-Schmidt R, Hilsted L, Bundgaard H, Nielsen S, Iversen K, Garred P. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk. Nature Communications 2023, 14: 5624. PMID: 37699890, PMCID: PMC10497567, DOI: 10.1038/s41467-023-41342-2.Peer-Reviewed Original ResearchConceptsImmune responseImmune imprintingOmicron infectionIgA responsesPrimary infectionSARS-CoV-2 immune responseSARS-CoV-2 infectionT cell immune responsesBreakthrough infection riskRobust humoral responseT cell responsesBNT162b2 vaccineHybrid immunityBooster vaccinationPrevious immunityVaccinated individualsHumoral responseLow IgGViral exposurePrevious infectionSubsequent reinfectionHigh riskVaccinationOmicron variantFuture infectionsRevaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C, Thomsen M, Andersen J, Jensen J, Bayarri-Olmos R, Garred P, Hermansen M, Johannsen A, Larsen M, Mistegaard C, Mikkelsen S, Nielsen L, Olesen R, Pérez-Alós L, Vils S, Szabados F, Søgaard O, Tolstrup M, Erikstrup C, Hauge E, Troldborg A. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients. Clinical And Experimental Rheumatology 2023, 42: 157-165. PMID: 37877429, DOI: 10.55563/clinexprheumatol/orpp04.Peer-Reviewed Original ResearchT cell responsesDetectable antibody responseBlood donorsSARS-CoV-2Antibody responseB cellsRheumatic diseasesCOVID-19 vaccine responsesSARS-CoV-2 antibodiesCOVID-19 mRNA vaccinesRevaccination of patientsSystemic lupus erythematosusB cell levelsCOVID-19 vaccinationPercent of casesDetectable serological responsesSARS-CoV-2 spike proteinAntibody class switchRD cohortLupus erythematosusVaccine responsesAntibody levelsRheumatoid arthritisSpecific IgGMRNA vaccinesShort-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
Madsen J, Holm B, Pérez-Alós L, Bayarri-Olmos R, Rosbjerg A, Fogh K, Pries-Heje M, Møller D, Hansen C, Heftdal L, Hasselbalch R, Hamm S, Frikke-Schmidt R, Hilsted L, Nielsen S, Iversen K, Bundgaard H, Garred P. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination. Microbiology Spectrum 2023, 11: e04947-22. PMID: 36877077, PMCID: PMC10101069, DOI: 10.1128/spectrum.04947-22.Peer-Reviewed Original ResearchSARS-CoV-2Salivary immunityIgG levelsBNT162b2 vaccinationFirst vaccinationSARS-CoV-2-infected individualsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 vaccinationSARS-CoV-2 IgGSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Prospective observational studyTime pointsSerum IgG levelsHigher IgG levelsSyndrome coronavirus 2Copenhagen University HospitalEffect of vaccinationHealth care professionalsBNT162b2 vaccineHybrid immunitySystemic vaccinationDetectable IgGSalivary IgG
2022
Enzyme-Linked Immunosorbent Assay for Activation of the Classical Complement Pathway by Plasmodium falciparum-Infected Erythrocyte Surface Antigen-Specific Antibodies
Larsen M, Bayarri-Olmos R, Garred P, Hviid L. Enzyme-Linked Immunosorbent Assay for Activation of the Classical Complement Pathway by Plasmodium falciparum-Infected Erythrocyte Surface Antigen-Specific Antibodies. Methods In Molecular Biology 2022, 2470: 673-678. PMID: 35881382, DOI: 10.1007/978-1-0716-2189-9_50.Peer-Reviewed Original ResearchConceptsClassical complement pathwayComplement pathwayAntigen-specific antibodiesInnate immune systemEnzyme-linked immunosorbentErythrocyte surface antigenAntibody titer determinationSurface antigenImmune systemComplement cascadeImmunosorbent assayMonoclonal antibodiesBiological cascadeAntibodiesTiter determinationActivationPathwayAntigenImmunosorbentELISALectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19
Götz M, Skjoedt M, Bayarri-Olmos R, Hansen C, Pérez-Alós L, Jarlhelt I, Benfield T, Rosbjerg A, Garred P. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19. Journal Of Innate Immunity 2022, 15: 122-135. PMID: 35816998, PMCID: PMC10643890, DOI: 10.1159/000525508.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsMASP-2 concentrationsHealthy controlsComplement activationConvalescent COVID-19 patientsNovel mouse monoclonal antibodyCOVID-19 pathophysiologyC-reactive proteinSandwich ELISAMASP-2Coronavirus disease 2019COVID-19Serine protease 2Downstream complement activationTerminal complement complexMouse monoclonal antibodyInflammatory markersConvalescent samplesMannose-binding lectinLectin complement pathwayDisease 2019Ficolin-3PatientsPossible associationFicolin-2Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
Harboe Z, Hamm S, Pérez-Alós L, Sivapalan P, Priemé H, Wilcke T, Kjeldgaard P, Shaker S, Jordan A, Møller D, Heftdal L, Madsen J, Bayarri-Olmos R, Hansen C, Pries-Heje M, Hasselbalch R, Fogh K, Armenteros J, Hilsted L, Sørensen E, Lindegaard B, Browatzki A, Biering-Sørensen T, Frikke-Schmidt R, Ostrowski S, Iversen K, Bundgaard H, Nielsen S, Garred P, Jensen J. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research 2022, 9: e001268. PMID: 35793836, PMCID: PMC9260234, DOI: 10.1136/bmjresp-2022-001268.Peer-Reviewed Original ResearchConceptsChronic pulmonary diseaseCOVID-19 vaccinationPulmonary diseaseLow respondersRisk factorsHumoral responseBNT162b2 mRNA COVID-19 vaccineBNT162b2 COVID-19 vaccinationMRNA COVID-19 vaccineCharlson Comorbidity IndexProspective cohort studyUse of prednisolonePoor immunological responseFunctional humoral responseCOVID-19 vaccineAU/mLComorbidity indexCohort studyFirst vaccinationSecondary outcomesPrimary outcomeRBD IgGAntibody responseImmunological outcomesAntibody index